Inappropriate expression of SETD2 and resulting errors in H3K36 trimethylation have been linked to various types of malignancies [5], for example human breast cancer [6], clear cell renal cell carcinoma (cRCC) [7], and systemic mastocytosis (SM) [8]. Here, SETD2 is linked to systemic mastocytosis.